Inclusion of compliance and persistence in economic models: Past, present and future

Applied Health Economics and Health Policy

Volumn 10, Issue 6, 2012, Pages 365-379

  Kadambi, Ananth ^a   Leipold, Robert J ^a   Kansal, Anuraag R ^a   Sorensen, Sonja ^a   Getsios, Denis ^a  

^a UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Cost effectiveness; Modelling; Patient compliance

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; EXENDIN 4; HALOPERIDOL; INSULIN GLARGINE; LOW MOLECULAR WEIGHT HEPARIN; OLANZAPINE; PROTON PUMP INHIBITOR; RISPERIDONE;

ACCOUNTING; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANKYLOSING SPONDYLITIS; BRONCHITIS; BUDGET; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DOCUMENTATION; DRUG COST; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECONOMIC ASPECT; HEALTH CARE COST; HEPATITIS B; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MODEL; MULTIPLE SCLEROSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCHIZOPHRENIA; SIMULATION; TREATMENT REFUSAL; TUBERCULOSIS; UTERINE CERVIX CANCER;

FORECASTING; HUMANS; MEDICATION ADHERENCE; MODELS, ECONOMIC; PATIENT COMPLIANCE;

EID: 84868278709     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.2165/11640590-000000000-00000     Document Type: Review

References (68)

1. Nasseh K, Frazee SG, Visaria J, et al. Cost of medication nonadherence associated with diabetes, hypertension, and dyslipidemia. Am J Pharm Benefits 2012; 4 (2): e41-7
2. Damen J, Thuresson PO, Heeg B, et al. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy 2008; 6 (4): 189-97
3. Hughes D, Cowell W, Koncz T, et al., International Society for Pharmacoeconomics and Outcomes Research Eco nomics of Medication Compliance Working Group. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007 Nov-Dec; 10 (6): 498-509 (Pubitemid 350013268)
4. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11 (1): 44-7 (Pubitemid 351160875)
5. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012 May; 73 (5): 691-705
6. Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance: room for methodological improvement. Health Policy 2002 Jan; 59 (1): 65-94 (Pubitemid 34098770)
7. Rosen AB, Spaulding AB, Greenberg D, et al. Patient adherence: a blind spot in cost-effectiveness analyses? Am J Manag Care 2009 Sep; 15 (9): 626-32
8. Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001; 19 (12): 1185-97 (Pubitemid 34074782)
9. Park SY, Lee EK. Methods and impact of incorporating medication compliance into pharmacoeconomic evaluations [abstract]. Value Health 2010; 13 (7): A331
10. Buckley PF, Wirshing DA, Bhushan P, et al. Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 2007; 21 (2): 129-41
11. Mann DM, Allegrante JP, Natarajan S, et al. Predictors of adherence to statins for primary prevention. Cardiovasc Drugs Ther 2007 Aug; 21 (4): 311-6 (Pubitemid 47387472)
12. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005 Jul-Aug; 8 (4): 495-505 (Pubitemid 41726103)
13. Kanis JA, Cooper C, Hiligsmann M, et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int 2011; 22 (10): 2565-73
14. Hiligsmann M, Boonen A, Rabenda V, et al. The importance of integrating medication adherence in pharm-acoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res 2012 Apr; 12 (2): 159-66
15. Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005; 53 (10): 1697-704 (Pubitemid 43109932)
16. Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. J Am Med Assoc 2007; 298 (6): 629-37 (Pubitemid 47236414)
17. Hiligsmann M, Gathon HJ, Bruyere O, et al. Costeffectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 2010; 13 (4): 394-401
18. Hiligsmann M, Rabenda V, Bruyere O, et al. The clinical and economic burden of non-adherence with oral bisphos-phonates in osteoporotic patients. Health Policy 2010; 96(2): 170-7
19. Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010; 86 (3): 202-10
20. Sander B, Elliot-Gibson V, Beaton DE, et al. A coordinator program in post-fracture osteoporosis management improves outcomes and saves costs. J Bone Joint Surg Am 2008; 90 (6): 1197-205 (Pubitemid 351778125)
21. Patrick AR, Schousboe JT, Losina E, et al. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J Clin En-docrinol Metab 2011; 96 (9): 2762-70
22. Jonsson B, Strom O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011; 22 (3): 967-82
23. Cotte FE, De Pouvourville G. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv Res 2011; 11: 151
24. Cotte FE, Fautrel B, De Pouvourville G. A Markov model simulation of the impact of treatment persistence in post-menopausal osteoporosis. Med Decis Making 2009 Jan-Feb; 29 (1): 125-39
25. Earnshaw SR, Graham CN, Ettinger B, et al. Costeffectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphos-phonates. Curr Med Res Opin 2007; 23 (10): 2517-29 (Pubitemid 350033454)
26. Strom O, Borgstrom F, Kanis JA, et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 2009; 20 (1): 23-34
27. Thompson M, Pasquale M, Grima D, et al. The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis. Value Health 2010; 13 (1): 46-54
28. Kelton CML, Pasquale MK. Evaluating the claim of enhanced persistence: the case of osteoporosis and implications for payers. Med Decis Making 2009; 29 (6): 690-706
29. Hiligsmann M, Ethgen O, Bruyere O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009; 12 (5): 687-96
30. Danese MD, Badamgarav E, Bauer DC. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J Bone Miner Res 2009; 24 (11): 1819-26
31. Heeg BMS, Buskens E, Knapp M, et al. Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics 2005; 23 Suppl. 1: 17-33
32. Laux G, Heeg BMS, van Hout BA, et al. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmaco-economics 2005; 23 Suppl. 1: 49-61
33. Chue PS, Heeg B, Buskens E, et al. Modelling the impact of compliance on the costs and effects of long-acting risper-idone in Canada. Pharmacoeconomics 2005; 23 Suppl. 1: 62-74
34. Heeg BMS, Antunes J, Figueira ML, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise. Curr Med Res Opin 2008; 24 (2): 349-58 (Pubitemid 351294384)
35. Dinh TA, Alperin P, Walter LC, et al. Impact of comorbidity on colorectal cancer screening cost-effectiveness study in diabetic populations. J Gen Intern Med 2012; 27 (6): 730-8
36. Hassan C, Hunink MGM, Laghi A, et al. Value-ofinformation analysis to guide future research in colorectal cancer screening. Radiology 2009; 253 (3): 745-52
37. Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, et al. Costeffectiveness of computed tomographic colonography screening for colorectal cancer in the Medicare population. J Natl Cancer Inst 2010; 102 (16): 1238-52
38. Parekh M, Fendrick AM, Ladabaum U. As tests evolve and costs of cancer care rise: reappraising stool-based screening for colorectal neoplasia. Aliment Pharmacol Ther 2008; 27 (8): 697-712 (Pubitemid 351406306)
39. Park SM, Yun YH, Kwon S. Feasible economic strategies to improve screening compliance for colorectal cancer in Korea. World J Gastroenterol 2005; 11 (11): 1587-93 (Pubitemid 40520796)
40. Parkin DM, Tappenden P, Olsen AH, et al. Predicting the impact of the screening programme for colorectal cancer in the UK. J Med Screen 2008; 15 (4): 163-74
41. Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, et al. Comparative economic evaluation of data from the ACRIN national CT colonography trial with three cancer intervention and surveillance modeling network micro-simulations. Radiology 2011; 261 (2): 487-98
42. Koong SL, Yen AM, Chen TH. Efficacy and costeffectiveness of nationwide cervical cancer screening in Taiwan. J Med Screen 2006; 13 Suppl. 1: S44-7
43. Dinh TA, Rosner BI, Atwood JC, et al. Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res 2011; 4 (1): 9-22
44. Lachaine J, Merikle E, Tarride JE, et al. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets. Clin Ther 2007; 29 (3): 519-28 (Pubitemid 46907286)
45. Greving JP, Visseren FL, de Wit GA, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 2011; 342: d1672
46. Stafilas PC, Sarafidis PA, Lasaridis AN, et al. An economic evaluation of the 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of mild-to-moderate hypertension in Greece. Am J Hypertens 2005; 18 (9): 1233-40 (Pubitemid 41337977)
47. Saini SD, Fendrick AM, Scheiman JM. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther 2011; 34 (2): 243-51
48. Sud S, Mittmann N, Cook DJ, et al. Screening and prevention of venous thromboembolism in critically ill patients: a decision analysis and economic evaluation. Am J Respir Crit Care Med 2011; 184 (11): 1289-98
49. Woehl A, Evans M, Tetlow AP, et al. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. Cardiovasc Diabetol 2008; 7: 24
50. Shaya FT, Sohn K, Lee S, et al. Clinical and economic evaluation of exenatide for formulary decisions. J Med Econ 2007; 10 (4): 529-37
51. Munakata J, Benner JS, Becker S, et al. Clinical and economic outcomes of nonadherence to highly active antire-troviral therapy in patients with human immunodeficiency virus. Med Care 2006; 44 (10): 893-9 (Pubitemid 44454565)
52. Sorensen SV, Baker T, Fleurence R, et al. Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis. Int J Tuberc Lung Dis 2009; 13 (8): 945-54
53. Holland DP, Sanders GD, Hamilton CD, et al. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med 2009; 179 (11): 1055-60
54. Uzochukwu BS, Obikeze EN, Onwujekwe OE, et al. Costeffectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT. Malar J 2009; 8: 265
55. Marra F, Marra CA, Sadatsafavi M, et al. Cost-effectiveness of a new interferon-based blood assay, QuantiFERON®-TB Gold, in screening tuberculosis contacts. Int J Tuberc Lung Dis 2008; 12 (12): 1414-24
56. Tan M, Menzies D, Schwartzman K. Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis. BMC Public Health 2008; 8: 201
57. Veldhuijzen IK, Toy M, Hahne SJM, et al. Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology 2010; 138 (2): 522-30
58. Thiry N, De Laet C, Hulstaert F, et al. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009; 25 (2): 161-70
59. Kobelt G, Andlin-Sobocki P, Maksymowych WP. The costeffectiveness of infliximab (Remicade®) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006; 33 (4): 732-40
60. Tappenden P, McCabe C, Chilcott J, et al. Costeffectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009; 12 (5): 657-65
61. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009; 15 (7): 543-55
62. Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008 Sep; 23 (9): 1435-41
63. Ndubuka NO, Ehlers VJ. Adult patients' adherence to antiretroviral treatment: a survey correlating pharmacy refill records and pill counts with immunological and virological indices. Int J Nurs Stud 2011 Nov; 48 (11): 1323-9
64. Lin HC, Erickson S, Smith D, et al. Antidepressant utilization, adherence and health care spending in the United States: the case of MDD patients 2000-2007. Value Health 2010; 13 (7): A454-5
65. Yang YK, Tarn YH, Wang TY, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. Psychiatr Clin Neu-rosci 2005; 59 (4): 385-94 (Pubitemid 41139546)
66. Bradley CT, Brasel KJ, Miller JJ, et al. Cost-effectiveness of prolonged thromboprophylaxis after cancer surgery. Ann Surg Oncol 2010; 17 (1): 31-9
67. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009 Dec; 20 (12): 2127-34
68. Perlroth DJ, Glass RJ, Davey VJ, et al. Health outcomes and costs of community mitigation strategies for an influenza pandemic in the United States. Clin Infect Dis 2010; 50 (2): 165-74